Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.

Clinical Drug Investigation
Ming-Mo HouJohn Wen-Cheng Chang

Abstract

Sorafenib, a multikinase inhibitor of tumour-cell proliferation and angiogenesis, has been shown to have a role in the treatment of metastatic renal cell carcinoma (RCC). Xp11 translocation carcinoma is a rare subtype of RCC. We report an 18-year-old male patient with metastatic Xp11 translocation RCC who was responsive to sorafenib treatment. Six weeks after commencement of treatment with sorafenib, a CT scan of the patient showed increased central necrosis of the kidney mass and para-aortic lymph nodes as well as regression of the lung and pleural masses. The patient had a progression-free survival of 12 months, and overall survival of 15 months. The most severe adverse effects were grade 3 dermatitis and grade 3 anaemia. This case has demonstrated for the first time that sorafenib is active against Xp11 translocation RCC.

References

Dec 24, 1996·Proceedings of the National Academy of Sciences of the United States of America·M A WetermanA Geurts van Kessel
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Jun 5, 2003·Cancer Genetics and Cytogenetics·Christine PérotJérôme Couturier
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Aug 19, 2004·The American Journal of Surgical Pathology·Elisabeth BruderHolger Moch
Apr 26, 2005·Clinics in Laboratory Medicine·Pedram Argani, Marc Ladanyi
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Jun 21, 2007·American Journal of Clinical Pathology·Paul N MeyerMaria M Picken

❮ Previous
Next ❯

Citations

Apr 30, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Bellmunt, J Dutcher
Dec 7, 2013·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Carla L EllisPedram Argani
Mar 30, 2011·Expert Opinion on Investigational Drugs·Liu HongDaiming Fan
Dec 17, 2015·Clinical and Experimental Dermatology·Z Z N YiuC E M Griffiths
Dec 8, 2019·Cancer Metastasis Reviews·Amy L WalzJames I Geller
Jul 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Bellmunt, J Dutcher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.